Table 1.
Baseline characteristics and quality assessment of the included studies.
| Author | Yr | Study design | Sample size | Sex (male/female) | Age | Duration of disease (yr) | Measurements | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Combined treatment group | Control group | Combined treatment group | Control group | Combined treatment group | Control group | Combined treatment group | Control group | Combined treatment group | Control group | |||
| Haizhen[15] | 2019 | RCT | 54 | 54 | 30/24 | 28/26 | 41.4 ± 11.5 | 41.9 ± 11.3 | 2.3 ± 0.7 | 2.5 ± 0.7 | Baogan Jiangzhi Decoction + Silibinin Capsules | Silibinin Capsules |
| Zhang et al[16] | 2020 | RCT | 30 | 30 | 24/6 | 23/7 | 48.5 ± 9.4 | 50.2 ± 7.2 | 3.3 ± 1.2 | 3.1 ± 1.0 | Baogan Jiedu Decoction + Silibinin Capsules | Silibinin Capsules |
| Hui and Wei[17] | 2018 | RCT | 50 | 50 | 27/23 | 24/26 | 45.9 ± 12.0 | 44.6 ± 11.7 | / | / | Danshao Shugan Granules + Silibinin Capsules | Silibinin Capsules |
| Xiaofeng et al[18] | 2016 | RCT | 40 | 40 | 32/8 | 31/9 | 44.9 | 45.2 | 1 | 1 | Gan Zhi Ping Granule + Silibinin Capsules | Silibinin Capsules |
| Ying et al[19] | 2018 | RCT | 25 | 25 | 15/10 | 14/11 | 34.5 ± 6.6 | 33.8 ± 7.0 | 5.2 ± 1.6 | 5.3 ± 2.0 | Huanglian Jiedu Decoction + Silibinin Capsules | Silibinin Capsules |
| Jie et al[20] | 2010 | RCT | 33 | 32 | 20/13 | 18/14 | 36.8 ± 11.7 | 38.3 ± 12.8 | / | / | Jianpi Shugan Granules + Silibinin Capsules | Silibinin Capsules |
| Nan et al[21] | 2015 | RCT | 42 | 42 | 21/21 | 20/22 | 36.7 ± 8.6 | 37.3 ± 11.7 | / | / | Jianpi Shugan Granules + Silibinin Capsules | Silibinin Capsules |
| Zhang et al[22] | 2018 | RCT | 46 | 46 | 9/37 | 8/38 | 52.9 ± 9.4 | 53.0 ± 9.4 | 4.5 ± 1.9 | 4.4 ± 2.0 | Jiangzhi Ligan Decoction + Silibinin Capsules | Silibinin Capsules |
| Shi[23] | 2023 | RCT | 40 | 40 | 28/12 | 30/10 | 40.2 ± 3.1 | 41.3 ± 2.8 | 1.3 ± 0.2 | 1.4 ± 0.1 | Qinggan Huashi Huoxue Decoction + Silibinin Capsules | Silibinin Capsules |
| Qi et al[24] | 2015 | RCT | 45 | 45 | 30/15 | 31/14 | 47.8 ± 9.6 | 43.6 ± 12.0 | 1.4 ± 1.2 | 1.7 ± 1.3 | Shugan Jianpi Decoction + Silibinin Capsules | Silibinin Capsules |
| Lin and Qing[25] | 2017 | RCT | 24 | 24 | 12/12 | 12/12 | 45–65 | 44–66 | / | / | Self-Proposed TCM Prescription + Silibinin Capsules | Silibinin Capsules |
| Panyu et al[26] | 2021 | RCT | 54 | 54 | 25/29 | 26/28 | 53.2 ± 8.3 | 52.8 ± 8.7 | 1.5 ± 0.2 | 1.5 ± 0.2 | Xiaozhi Hugan Decoction + Silibinin Capsules | Silibinin Capsules |
| Yue et al[27] | 2015 | RCT | 35 | 35 | 28/7 | 30/5 | 18–56 | 20–54 | / | / | Xingqi Huatan Method + Silibinin Capsules | Silibinin Capsules |
| Yan and Jie[28] | 2019 | RCT | 56 | 54 | 45/11 | 40/14 | 25–65 | 20–66 | / | / | Quzhi Prescription + Silibinin Capsules | Silibinin Capsules |
| Shuan-Shuang et al[29] | 2022 | RCT | 60 | 60 | 28/32 | 36/24 | 47.4 ± 11.8 | 46.7 ± 12.2 | 2.0 ± 1.2 | 2.2 ± 1.2 | Self-Proposed Xiaopi Huatan Granules + Silibinin Capsules | Silibinin Capsules |
| Kaijie et al[30] | 2021 | RCT | 35 | 35 | 23/12 | 21/14 | 42.4 ± 4.6 | 43.2 ± 5.1 | 4.1 ± 1.7 | 4.2 ± 1.9 | Self-Proposed TCM Prescription + Silibinin Capsules | Silibinin Capsules |
RCT = randomized controlled trial, TCM = traditional Chinese medicine.